Drug Profile
Ibrutinib - Janssen/Pharmacyclics
Alternative Names: CRA-032765; IMBRUVICA; Imbruvica; ImBurvica; JNJ-54179060; PCI-32765Latest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator Celera Genomics Group
- Developer Bristol-Myers Squibb; Celgene Corporation; Foundation GIMEMA; Genentech; Janssen; Janssen Biotech; Lymphoma Academic Research Organisation; National Cancer Institute (USA); Northwestern University; OHSU Knight Cancer Institute; Pharmacyclics; Sheba Medical Center; Singapore General Hospital; Stanford University Medical Center; Thomas Jefferson University; University Hospital Muenster; University of California, Davis; University of California, San Diego
- Class 2 ring heterocyclic compounds; Antiallergics; Antineoplastics; Antirheumatics; Phenyl ethers; Piperidines; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Emt protein-tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Graft-versus-host disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Phase III Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Pancreatic cancer
- Phase II Acute myeloid leukaemia; B-cell lymphoma; CNS cancer; Hairy cell leukaemia; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; SARS-CoV-2 acute respiratory disease; Solid tumours; Squamous cell cancer; T-cell prolymphocytic leukaemia
- Phase I/II Gastrointestinal cancer; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
- No development reported Cancer; Colorectal cancer; Lymphoma; Myelodysplastic syndromes
- Discontinued Breast cancer; Rheumatoid arthritis; Seasonal allergic rhinitis
Most Recent Events
- 27 Mar 2024 Pharmacyclics and Janssen Research and Development completes the phase II CAPTIVATE trial in Chronic lymphocytic leukaemia (Combination therapy, First line therapy) in USA, Australia, Italy, New Zealand, Spain and Poland (NCT02910583)
- 01 Feb 2024 Janssen Research & Development initiates enrolment in the phase-II TAILOR trial for Chronic lymphocytic leukaemia (Combination therapy, Monotherapy, First-line therapy) in USA (NCT05963074),
- 02 Jan 2024 The University of Birmingham completes the phase II IciCLLe trial for Chronic lymphocytic leukaemia in United Kingdom (ISRCTN12695354) ( EudraCT2012-003608-11)